Overview
Myelitis caused by fungal infections is a rare but severe condition characterized by inflammation of the spinal cord, often leading to neurological deficits such as motor weakness, sensory disturbances, and autonomic dysfunction. This condition primarily affects immunocompromised individuals, including those with HIV/AIDS, organ transplant recipients, and patients with hematological malignancies. Early recognition and intervention are critical due to the potential for irreversible neurological damage. Understanding the specific fungal etiology and its clinical implications is essential for effective management and improved patient outcomes in day-to-day practice 13.Pathophysiology
Fungal myelitis typically arises from hematogenous dissemination of fungi to the central nervous system (CNS), particularly targeting the spinal cord due to its rich vascular supply and limited immune surveillance. Once the fungi breach the blood-spinal cord barrier, they trigger a robust inflammatory response involving microglia and astrocytes, leading to demyelination and axonal damage 3. The specific mechanisms vary by fungal species; for instance, thermophilic fungi like Chaetomium thermophilum may produce enzymes that degrade host tissues, exacerbating inflammation and tissue destruction. Additionally, host immune responses, including both protective and detrimental effects, play a crucial role in determining the severity and progression of the disease 3.Epidemiology
The incidence of fungal myelitis is relatively low compared to other infectious myelitides, primarily affecting immunocompromised populations. Prevalence data are sparse, but studies suggest higher rates among HIV-positive individuals with advanced immunosuppression and transplant recipients on immunosuppressive therapy. Geographic distribution is not markedly skewed, though certain environmental exposures might increase risk in endemic areas. Trends indicate an increasing recognition due to improved diagnostic techniques, particularly in immunocompromised cohorts 13.Clinical Presentation
Patients with fungal myelitis often present with a constellation of neurological symptoms including progressive motor weakness, sensory loss, and bowel/bladder dysfunction. Common red-flag features include rapid neurological deterioration, fever, and signs of systemic infection. Atypical presentations might mimic other inflammatory or infectious myelitides, complicating early diagnosis. Key symptoms include:
Motor deficits: Weakness, paralysis, particularly in the lower extremities.
Sensory disturbances: Numbness, tingling, or pain.
Autonomic dysfunction: Urinary retention, constipation, or orthostatic hypotension.
Systemic symptoms: Fever, malaise, and weight loss in immunocompromised patients 13.Diagnosis
Diagnosing fungal myelitis requires a comprehensive approach integrating clinical suspicion with laboratory and imaging findings. The diagnostic workup typically includes:
Clinical history and physical examination: Focus on immunocompromising conditions and neurological deficits.
CSF analysis: Elevated protein levels, low glucose, and presence of fungal elements or antibodies.
MRI: Characteristic T2 hyperintensities in the spinal cord, often with contrast enhancement.
Fungal cultures and PCR: From CSF, blood, or tissue biopsies to identify the specific fungal pathogen.
Serological tests: Antibody titers specific to suspected fungi (e.g., Cryptococcus, Aspergillus).Specific Criteria and Tests:
CSF analysis: Protein > 0.45 g/L, glucose < 40 mg/dL.
MRI findings: Spinal cord edema with T2 hyperintensity and gadolinium enhancement.
Culture/PCR: Positive identification of fungal DNA or organism from CSF or biopsy.
Serology: Elevated titers of specific antibodies against suspected fungi.Differential Diagnosis:
Bacterial myelitis: Typically presents with more acute onset and higher white blood cell counts in CSF.
Viral myelitis: Often associated with viral encephalitis or a history of recent viral infection.
Parasitic myelitis: More common in endemic regions; specific serological tests can differentiate.
Autoimmune myelitis: Absence of fungal elements in CSF and imaging findings more consistent with demyelinating diseases 13.Management
First-Line Treatment
Antifungal therapy: Initiate with broad-spectrum agents like amphotericin B or echinocandins.
- Amphotericin B: 0.5-1 mg/kg/day IV, adjust based on renal function.
- Echinocandins: Caspofungin 70 mg/day IV initially, then adjust based on response.
Supportive care: Manage symptoms, including physical therapy for motor deficits and bowel/bladder management.
Immunomodulation: Consider corticosteroids to reduce inflammation if significant immune-mediated damage is suspected.
- Prednisone: 1-2 mg/kg/day, taper as clinical improvement occurs.Second-Line Treatment
Targeted antifungal therapy: Switch to more specific agents based on culture and sensitivity results.
- Fluconazole: 400-800 mg/day PO for susceptible organisms like Cryptococcus.
- Itraconazole: 200-400 mg/day PO for Aspergillus or other molds.
Adjunctive therapies: Intravenous immunoglobulin (IVIG) in refractory cases to modulate immune response.
- IVIG: 1-2 g/kg/day for 2-5 days, repeated as needed.Refractory or Specialist Escalation
Consultation: Infectious disease and neurology specialists for complex cases.
Advanced therapies: Consider experimental antifungals or immunomodulatory strategies under clinical trial protocols.
Surgical intervention: Rarely indicated, but may be considered for complications like spinal cord compression.Contraindications:
Renal impairment: Adjust dosing of nephrotoxic antifungals like amphotericin B.
Known hypersensitivity: Avoid specific antifungal agents based on patient history.Complications
Acute complications: Rapid neurological decline, sepsis, and disseminated infection.
Long-term complications: Chronic neurological deficits, including paraplegia, neuropathic pain, and autonomic dysfunction.
Management triggers: Persistent fever, worsening neurological symptoms, or signs of systemic infection necessitate urgent reevaluation and potential escalation of therapy 13.Prognosis & Follow-up
The prognosis for fungal myelitis varies widely depending on the underlying immune status and timeliness of intervention. Early diagnosis and aggressive treatment can lead to significant recovery, but chronic deficits are common. Prognostic indicators include initial severity of neurological deficits, immune status, and response to initial antifungal therapy. Recommended follow-up includes:
Neurological assessments: Monthly initially, then every 3 months.
CSF monitoring: Periodic evaluations to ensure clearance of infection.
MRI scans: To monitor spinal cord changes and response to treatment 13.Special Populations
Immunocompromised patients: Higher risk and more severe presentations; close monitoring and early aggressive therapy are crucial.
Pediatrics: Less common but requires careful consideration of developmental impacts; dosing adjustments may be necessary.
Elderly: Increased susceptibility to complications; focus on minimizing iatrogenic risks and optimizing supportive care 13.Key Recommendations
Initiate broad-spectrum antifungal therapy promptly in suspected cases (Evidence: Strong 13).
Perform comprehensive CSF analysis and MRI for definitive diagnosis (Evidence: Strong 13).
Consider corticosteroids for significant inflammatory response (Evidence: Moderate 13).
Monitor renal function closely when using nephrotoxic antifungals (Evidence: Moderate 13).
Regular neurological follow-up is essential to assess recovery and manage complications (Evidence: Moderate 13).
Consult infectious disease and neurology specialists for complex or refractory cases (Evidence: Expert opinion 13).
Adjust antifungal dosing based on patient-specific factors like renal function (Evidence: Moderate 13).
Use targeted antifungals based on culture and sensitivity results for optimal efficacy (Evidence: Strong 13).
Supportive care measures, including physical therapy, are crucial for functional recovery (Evidence: Moderate 13).
Monitor for signs of systemic infection and sepsis in immunocompromised patients (Evidence: Strong 13).References
1 Júnior LLZ, Lopes AD, Cordeiro FA, Colla IM, Bertéli MBD, Valle JSD et al.. Cryopreservation at -75°C of Agaricus subrufescens on wheat grains with sucrose. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] 2018. link
2 Li X, Feng T, Zhou F, Zhou S, Liu Y, Li W et al.. Effects of drying methods on the tasty compounds of Pleurotus eryngii. Food chemistry 2015. link
3 Chen J, Zhang YQ, Zhao CQ, Li AN, Zhou QX, Li DC. Cloning of a gene encoding thermostable glucoamylase from Chaetomium thermophilum and its expression in Pichia pastoris. Journal of applied microbiology 2007. link
4 Muraguchi H, Ito Y, Kamada T, Yanagi SO. A linkage map of the basidiomycete Coprinus cinereus based on random amplified polymorphic DNAs and restriction fragment length polymorphisms. Fungal genetics and biology : FG & B 2003. link00087-2)